03:37 AM EDT, 04/04/2025 (MT Newswires) -- Mesoblast (MESO) said late Thursday it considers its allogeneic cellular therapies, including Ryoncil and Revascor, to be US-origin products that will not be subject to tariffs.
The company said its allogeneic cellular products "are manufactured from US donors in the US and designated as US origin products."